查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041780

祛痰藥市場預測至2034年－按產品類型、劑型、藥物類型、通路、最終用戶和地區分類的全球分析

Expectorant Drugs Market Forecasts to 2034 - Global Analysis By Product (Prescription Drug and Over the Counter (Otc)), Dosage Form (Oral Solid, Oral Liquid and Inhalant), Drug Type, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球祛痰藥市場規模將達到 259 億美元，並在預測期內以 14.9% 的複合年成長率成長，到 2034 年將達到 787 億美元。

祛痰藥主要用於幫助排放呼吸道（尤其是呼吸系統）中的黏液和分泌物。這類藥物能稀釋並軟化肺部黏液，使其更容易咳出。它們常用於排放咳嗽、鼻塞和呼吸道感染疾病等呼吸系統疾病的相關症狀。

根據美國國家生物技術資訊中心 (NCBI) 發布的數據，咳嗽相關問題約佔全球基層醫療醫生就診量的 8%。

呼吸系統疾病盛行率增加

隨著支氣管炎、慢性阻塞性肺病（COPD）、氣喘和呼吸道感染疾病等呼吸系統疾病患者人數的增加，對藥物，尤其是祛痰藥的需求也隨之成長。這些藥物在控制這些疾病的典型症狀（如痰液過多、咳嗽和胸悶）方面發揮著至關重要的作用。由於空氣污染、生活方式改變和傳染性病原體等因素導致呼吸系統疾病日益普遍，人們對祛痰藥緩解症狀和改善呼吸系統健康的需求持續成長，從而推動了市場發展。

副作用增加

由於報告的副作用數量不斷增加，祛痰藥市場正面臨嚴峻的限制。這些藥物旨在透過稀釋黏液來緩解呼吸道症狀，因此，諸如噁心、頭暈和過敏反應等副作用的增加會影響患者的耐受性和依從性。較高的副作用發生率會降低患者的依從性，削弱他們對這些藥物的信心，並最終影響市場需求。

技術進步

持續創新推動著祛痰藥配方的改進、給藥系統的最佳化以及療效的提升。新技術能夠將藥物靶向輸送到患處呼吸道，從而研發出最佳化治療效果和提高患者依從性的創新配方。此外，個人化醫療和藥物基因體學的進步正引領著針對患者個別情況的祛痰治療，有望實現更有效、更個人化的治療方案。擁抱這些進步將有助於滿足未被滿足的醫療需求，並推動祛痰藥市場的成長和創新。

監管障礙

複雜的法律規範、各地區的不同要求以及冗長的核准流程，都阻礙了新型祛痰藥的上市。克服這些障礙需要對研發進行大量投資，嚴格遵守監管準則，並與監管機構進行有效合作。如果無法應對這些挑戰，可能會阻礙創新祛痰藥的及時上市，並限制市場成長。

新冠疫情的感染疾病

由於人們越來越重視控制與新冠肺炎相關的咳嗽、胸悶等呼吸道症狀，祛痰藥的需求激增。疫情也促進了呼吸系統健康領域的研究，這可能有助於開發新型和改良的祛痰藥及其配方。此外，考慮到新冠肺炎對呼吸系統健康的長期影響以及潛在的長期呼吸問題，尤其是在疫情初期，對祛痰藥的需求可能會持續存在。

在預測期內，粘液溶解劑市場預計將佔據最大佔有率。

化痰藥預計將佔據最大的市場佔有率。化痰藥含有溴己新、乙醯半胱胺酸和氨溴索等成分，其作用機制是透過分解黏液中的化學鍵，降低黏液黏稠度，使其更容易透過咳嗽排放。祛痰藥用於治療多種呼吸系統疾病，如慢性支氣管炎、慢性阻塞性肺病（COPD）和囊腫纖維化，有助於清除過多黏液並緩解阻塞症狀。此外，化痰藥能夠靶向並改變粘液的特性，使其成為呼吸系統疾病治療中不可或缺的藥物。

在預測期內，醫院產業預計將呈現最高的複合年成長率。

預計在預測期內，醫院市場將呈現顯著成長。醫院是祛痰藥的主要買家和經銷商，因為它們是呼吸系統疾病診斷和治療的關鍵中心。本院採購各種祛痰藥，用於治療急性及慢性呼吸道疾病患者，包括肺炎、支氣管炎及慢性阻塞性肺病急性惡化。此外，醫院還會儲備這些藥物，以滿足因呼吸系統疾病、急診或慢性病管理入院患者的各種呼吸系統健康需求，從而顯著推動祛痰藥市場的需求。

市佔率最大的地區：

在預測期內，亞太地區佔據了最大的市場佔有率，這主要歸因於呼吸系統疾病的增加、污染程度的加劇以及大量人口受季節性性行為感染的影響。此外，都市化、生活方式的改變以及環境污染等因素也加劇了呼吸系統疾病，並推動了祛痰藥的需求。為確保民眾能夠負擔得起醫療保健服務所做的努力，以及主要市場參與者對研發的投入，都促進了亞太地區祛痰藥市場的快速成長，滿足了該地區人們多樣化的呼吸系統健康需求。

複合年成長率最高的地區：

在北美，支氣管炎、流感和過敏等疾病的流行預計將在預測期內推動市場盈利成長。該地區完善的醫療保健基礎設施、先進的藥物研發以及公眾對呼吸系統健康問題的高度重視，都在推動市場成長。此外，藥物研發方面的策略性措施、健全的法規結構以及專注於創新和產品多元化的主要市場參與者，也進一步促進了北美祛痰藥市場的發展。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章：執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球祛痰藥市場：依產品分類

  • 處方藥
  • 非處方藥

第6章 全球祛痰藥市場：以劑型分類

  • 口服固態劑型
  • 口服液
  • 吸入劑

第7章 全球祛痰藥市場：依藥物類型分類

  • 分泌促效劑
    • 檸檬酸鉀
    • 檸檬酸鈉
    • 氯化銨
  • 祛痰藥
    • 溴己新
    • 氨溴索
    • 羧半胱氨酸
    • 乙醯半胱胺酸
  • 其他藥物類型

第8章 全球祛痰藥市場：依通路分類

  • 藥局
  • 零售店
  • 網路藥房
  • 其他分銷管道

第9章 全球祛痰藥市場：依最終用戶分類

  • 醫院
  • 專業醫療中心
  • 居家照護
  • 其他最終用戶

第10章 全球祛痰藥市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第11章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • Abbott Laboratories
  • Astrazeneca Plc.
  • Acella Pharmaceuticals LLC
  • Cipla Limited
  • Beckman Coulter Inc.
  • Mylan NV
  • GSK plc
  • Glenmark Pharmaceuticals Limited
  • Johnson and Johnson
  • Novartis International AG
  • Merck KGaA
  • Pfizer inc
  • Sanofi SA
  • Vernalis plc
  • Proctor and Gamble Co
  • Dahur india Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Tris Pharma Inc.
  • Aurobindo Pharma Ltd
  • Biocon
Product Code: SMRC24844

According to Stratistics MRC, the Global Expectorant Drugs Market is accounted for $25.9 billion in 2026 and is expected to reach $78.7 billion by 2034 growing at a CAGR of 14.9% during the forecast period. Expectorant drugs are medications primarily used to facilitate the removal of mucus and secretions from the airways, particularly in the respiratory tract. These drugs work by thinning and loosening mucus in the lungs, making it easier to cough up and expel. They are commonly used to alleviate symptoms associated with respiratory conditions such as cough, congestion, and respiratory infections.

According to data released by the National Center for Biotechnology Information, cough accounted for about 8% of all consultations with primary care physicians worldwide.

Market Dynamics:

Driver:

Rising prevalence of respiratory conditions

With an increasing number of individuals affected by respiratory ailments like bronchitis, COPD, asthma, and respiratory infections, the demand for medications, particularly expectorant drugs, rises correspondingly. These medications play a pivotal role in managing the hallmark symptoms of these conditions, such as excessive mucus production, coughing, and chest congestion. As respiratory illnesses become more commonplace due to factors like air pollution, changing lifestyles, and infectious agents, the consistent need for expectorant drugs to alleviate symptoms and improve respiratory health drives market growth.

Restraint:

Increased side effects

The market for expectorant drugs is severely constrained by the growing number of adverse effects. As these medications aim to alleviate respiratory symptoms by thinning mucus, the rise in reported adverse effects like nausea, dizziness, or allergic reactions impacts patient tolerance and compliance. Heightened occurrences of side effects can deter patient adherence, leading to reduced confidence in these medications and potentially affecting market demand.

Opportunity:

Advancements in technology

Ongoing innovations drive the development of advanced drug formulations, improved delivery systems, and enhanced efficacy of expectorant medications. Novel technologies facilitate targeted drug delivery to affected respiratory areas, creating innovative formulations that optimise treatment outcomes and patient compliance. Additionally, advancements in personalised medicine and pharmacogenomics may lead to tailored expectorant therapies, ensuring more effective and personalised treatment approaches. Embracing these advancements addresses unmet medical needs, fostering growth and innovation in the expectorant drugs market.

Threat:

Regulatory hurdles

Complex regulatory frameworks, diverse regional requirements, and extended approval timelines create obstacles for introducing new expectorant medications. Overcoming these hurdles demands substantial investments in research and development, meticulous adherence to stringent regulatory guidelines, and effective collaboration with regulatory bodies. Failure to navigate these challenges can impede the timely introduction of innovative expectorant drugs, limiting market growth.

Covid-19 Impact

There was a surge in demand for expectorant drugs due to the emphasis on managing respiratory symptoms associated with COVID-19, such as cough and chest congestion. The pandemic prompted increased research into respiratory health, potentially leading to the development of new and improved expectorant drugs or formulations. Furthermore, during the initial pandemic phase, there may be a continuing need for expectorant medications due to the COVID-19's long-lasting effects on respiratory health and possible long-term respiratory problems.

The mucolytics segment is expected to be the largest during the forecast period

The mucolytics segment is estimated to hold the largest share. Mucolytics contain agents such as bromhexine, acetylcysteine, or ambroxol that work by disrupting the chemical bonds within mucus, making it less viscous and easier to expel through coughing. Mucolytics find application in various respiratory conditions like chronic bronchitis, COPD (chronic obstructive pulmonary disease), and cystic fibrosis, aiding in the clearance of excessive mucus and alleviating symptoms of congestion. Furthermore, their ability to target and modify the properties of mucus makes them a crucial component in managing respiratory disorders.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to have lucrative growth during the forecast period. Hospitals serve as major purchasers and distributors of expectorant drugs due to their role as primary centres for diagnosing and treating respiratory conditions. They procure a wide range of expectorant medications to manage patients with acute and chronic respiratory ailments, including pneumonia, bronchitis, and COPD exacerbations. In addition, hospitals maintain adequate stocks of these drugs to address the diverse respiratory health needs of patients admitted for respiratory care, emergency treatments, or chronic disease management, thereby significantly contributing to the demand within the expectorant drug market.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to rising respiratory ailments, increasing pollution levels, and a larger population affected by seasonal infections. Furthermore, factors like urbanisation, changing lifestyles, and environmental pollutants contribute to respiratory issues, driving the demand for expectorant medications. Initiatives for affordable healthcare access and the presence of key market players investing in research and development contribute to the region's burgeoning expectorant drug market, catering to the diverse respiratory health needs of the Asia Pacific population.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to prevalent conditions like bronchitis, flu, and allergies. The region's robust healthcare infrastructure, advanced pharmaceutical research, and high awareness levels among the population about managing respiratory health issues foster market growth. Moreover, strategic initiatives for drug development, strong regulatory frameworks, and the presence of key market players focusing on innovation and product diversification further propel the North American expectorant drug market.

Key players in the market

Some of the key players in the Expectorant Drugs Market include Abbott Laboratories, Astrazeneca Plc., Acella Pharmaceuticals LLC, Cipla Limited, Beckman Coulter Inc., Mylan N.V., GSK plc, Glenmark Pharmaceuticals Limited, Johnson and Johnson, Novartis International AG, Merck KGaA, Pfizer inc, Sanofi SA, Vernalis plc, Proctor and Gamble Co, Dahur india Ltd, Teva Pharmaceutical Industries Ltd., Tris Pharma Inc., Aurobindo Pharma Ltd and Biocon.

Key Developments:

In October 2023, Efficient Laboratories, a Puerto Rican firm that distributes its brands of healthcare products, launched a new product, ROMPR PECHITO, an OTC medicine for children to relieve cold symptoms.

In September 2023, Genexa announced new clean over-the-counter (OTC) kids' medicines, further strengthening its leading role in bringing consumers clean, safe, and effective medications.

Products Covered:

  • Prescription Drug
  • Over the Counter (Otc)

Dosage Forms Covered:

  • Oral Solid
  • Oral Liquid
  • Inhalant

Drug Types Covered:

  • Secretion Enhancer
  • Mucolytics
  • Other Drug Types

Distribution Channels Covered:

  • Drug Store
  • Retail Store
  • Online Pharmacies
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Speciality Centres
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Expectorant Drugs Market, By Product

  • 5.1 Introduction
  • 5.2 Prescription Drug
  • 5.3 Over The Counter (Otc)

6 Global Expectorant Drugs Market, By Dosage Form

  • 6.1 Introduction
  • 6.2 Oral Solid
  • 6.7 Oral Liquid
  • 6.8 Inhalant

7 Global Expectorant Drugs Market, By Drug Type

  • 7.1 Introduction
  • 7.2 Secretion Enhancer
    • 7.2.1 Potassium Citrate
    • 7.2.2 Sodium Citrate
    • 7.2.3 Ammonium Chloride
  • 7.3 Mucolytics
    • 7.3.1 Bromhexine
    • 7.3.2 Ambroxol
    • 7.3.3 Carbocisteineurine
    • 7.3.4 Acetyl Cysteine
  • 7.4 Other Drug Types

8 Global Expectorant Drugs Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Drug Store
  • 8.3 Retail Store
  • 8.4 Online Pharmacies
  • 8.5 Other Distribution Channels

9 Global Expectorant Drugs Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Speciality Centres
  • 9.4 Homecare
  • 9.5 Other End Users

10 Global Expectorant Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 Astrazeneca Plc.
  • 12.3 Acella Pharmaceuticals LLC
  • 12.4 Cipla Limited
  • 12.5 Beckman Coulter Inc.
  • 12.6 Mylan N.V.
  • 12.7 GSK plc
  • 12.8 Glenmark Pharmaceuticals Limited
  • 12.9 Johnson and Johnson
  • 12.10 Novartis International AG
  • 12.11 Merck KGaA
  • 12.12 Pfizer inc
  • 12.13 Sanofi SA
  • 12.14 Vernalis plc
  • 12.15 Proctor and Gamble Co
  • 12.16 Dahur india Ltd
  • 12.17 Teva Pharmaceutical Industries Ltd.
  • 12.18 Tris Pharma Inc.
  • 12.19 Aurobindo Pharma Ltd
  • 12.20 Biocon

List of Tables

  • Table 1 Global Expectorant Drugs Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Expectorant Drugs Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Expectorant Drugs Market Outlook, By Prescription Drug (2023-2034) ($MN)
  • Table 4 Global Expectorant Drugs Market Outlook, By Over The Counter (Otc) (2023-2034) ($MN)
  • Table 5 Global Expectorant Drugs Market Outlook, By Dosage Form (2023-2034) ($MN)
  • Table 6 Global Expectorant Drugs Market Outlook, By Oral Solid (2023-2034) ($MN)
  • Table 7 Global Expectorant Drugs Market Outlook, By Oral Liquid (2023-2034) ($MN)
  • Table 8 Global Expectorant Drugs Market Outlook, By Inhalant (2023-2034) ($MN)
  • Table 9 Global Expectorant Drugs Market Outlook, By Drug Type (2023-2034) ($MN)
  • Table 10 Global Expectorant Drugs Market Outlook, By Secretion Enhancer (2023-2034) ($MN)
  • Table 11 Global Expectorant Drugs Market Outlook, By Potassium Citrate (2023-2034) ($MN)
  • Table 12 Global Expectorant Drugs Market Outlook, By Sodium Citrate (2023-2034) ($MN)
  • Table 13 Global Expectorant Drugs Market Outlook, By Ammonium Chloride (2023-2034) ($MN)
  • Table 14 Global Expectorant Drugs Market Outlook, By Mucolytics (2023-2034) ($MN)
  • Table 15 Global Expectorant Drugs Market Outlook, By Bromhexine (2023-2034) ($MN)
  • Table 16 Global Expectorant Drugs Market Outlook, By Ambroxol (2023-2034) ($MN)
  • Table 17 Global Expectorant Drugs Market Outlook, By Carbocisteineurine (2023-2034) ($MN)
  • Table 18 Global Expectorant Drugs Market Outlook, By Acetyl Cysteine (2023-2034) ($MN)
  • Table 19 Global Expectorant Drugs Market Outlook, By Other Drug Types (2023-2034) ($MN)
  • Table 20 Global Expectorant Drugs Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 21 Global Expectorant Drugs Market Outlook, By Drug Store (2023-2034) ($MN)
  • Table 22 Global Expectorant Drugs Market Outlook, By Retail Store (2023-2034) ($MN)
  • Table 23 Global Expectorant Drugs Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 24 Global Expectorant Drugs Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 25 Global Expectorant Drugs Market Outlook, By End User (2023-2034) ($MN)
  • Table 26 Global Expectorant Drugs Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 27 Global Expectorant Drugs Market Outlook, By Speciality Centres (2023-2034) ($MN)
  • Table 28 Global Expectorant Drugs Market Outlook, By Homecare (2023-2034) ($MN)
  • Table 29 Global Expectorant Drugs Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.